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refractory cardiogenic shock after adult
cardiac surgery: a systematic review and
meta-analysis
Maziar Khorsandi1*, Scott Dougherty2, Omar Bouamra3, Vasudev Pai4, Philip Curry1, Steven Tsui5, Stephen Clark6,
Stephen Westaby7, Nawwar Al-Attar1 and Vipin Zamvar8Abstract
Background: Postcardiotomy cardiogenic shock (PCCS) refractory to inotropic support and intra-aortic balloon
pump (IABP) occurs rarely but is almost universally fatal without mechanical circulatory support. In this systematic
review and meta-analysis we looked at the evidence behind the use of veno-arterial extra-corporeal membrane
oxygenation (VA ECMO) in refractory PCCS from a patient survival rate and determinants of outcome viewpoint.
Methods: A systematic review was performed in January 2017 using PubMed (with no defined time period) using
the keywords “postcardiotomy”, “cardiogenic shock”, “extracorporeal membrane oxygenation” and “cardiac surgery”.
We excluded papers pertaining to ECMO following paediatric cardiac surgery, medical causes of cardiogenic shock,
as well as case reports, review articles, expert opinions, and letters to the editor. Once the studies were collated,
a meta-analysis was performed on the proportion of survivors in those papers that met the inclusion criteria.
Meta-regression was performed for the most commonly reported adverse prognostic indicators (API).
Results: We identified 24 studies and a cumulative pool of 1926 patients from 1992 to 2016. We tabulated the
demographic data, including the strengths and weaknesses for each of the studies, outcomes of VA ECMO for
refractory PCCS, complications, and APIs. All the studies were retrospective cohort studies. Meta-analysis of the
moderately heterogeneous data (95% CI 0.29 to 0.34, p < 0.01, I2 = 60%) revealed overall survival rate to hospital
discharge of 30.8%. Some of the commonly reported APIs were advanced age (>70 years, 95% CI −0.057 to 0.001,
P = 0.058), and long ECMO support (95% CI −0.068 to 0.166, P = 0.412). Postoperative renal failure, high EuroSCORE
(>20%), diabetes mellitus, obesity, rising lactate whilst on ECMO, gastrointestinal complications had also been reported.
Conclusion: Haemodynamic support with VA ECMO provides a survival benefit with reasonable intermediate and
long-term outcomes. Many studies had reported advanced age, renal failure and prolonged VA ECMO support as the
most likely APIs for VA ECMO in PCCS. EuroSCORE can be utilized to anticipate the need for prophylactic perioperative
VA ECMO in the high-risk category. APIs can be used to aid decision-making regarding both the institution and
weaning of ECMO for refractory PCCS.
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Postcardiotomy cardiogenic shock (PCCS) refractory to
inotropic support and intra-aortic balloon counter pulsa-
tion (IABP) is an infrequent but almost universally fatal
condition without mechanical circulatory support (MCS)
[1–5]. Veno-Arterial (VA) extra-corporeal membrane
oxygenation (ECMO) has been utilized as a salvage MCS
after cardiac surgery for almost 50 years [6, 7]. The deci-
sions surrounding when best to institute or withdraw
such invasive and resource-intensive therapy remains
controversial and there are no universally agreed upon
guidelines on the indications for this therapy. VA ECMO
in the context of refractory PCCS is mainly instituted as
a temporizing measure as a “bridge to recovery” [5, 8, 9].
However, it has also been utilized as a “bridge to deci-
sion” and “destination therapy” with long-term implant-
able devices (e.g. left ventricular assist device, LVAD),
and more rarely in the UK, “bridge to orthotopic heart
transplantation (OHT)” [8–10]. Nevertheless, ECMO
carries with it a significant morbidity rate, often associ-
ated with prolonged hospital stays and poor quality of
life for the survivors after hospital discharge [5, 11].
In this systematic review and meta-analysis we have
looked at the survival rate following VA ECMO for
intractable PCCS in adults and some of the most com-
monly and consistently reported adverse prognostic indi-
cators (API) in this group of patients.
Methods
A comprehensive literature search was performed in
January 2017 using OVID/MEDLINE (PubMed) for all
articles published in the English language in peer-
reviewed journals. The inclusion criterion was post-
cardiotomy VA ECMO in adults. We excluded all
articles pertaining to VA ECMO for paediatric cardiac
surgery as well as non-surgical indications for the use
of this therapeutic modality e.g. myocarditis or cardio-
myopathy. We also excluded case reports, review arti-
cles, expert opinions, and letters to the editor.
The search was performed, with no limit to the year of
publication, using the following three search strategies:
Search 1: “(((Extracorporeal membrane oxygenation)
AND thoracic surgery) AND cardiac surgical procedures)
AND shock, cardiogenic”,
Search 2: “((Extracorporeal membrane[Title]) OR
ECMO[Title]) AND cardiac surgery[Title/Abstract]”.
Search 3: “(((Extracorporeal membrane[Title]) OR
ECMO[Title]) AND postcardiotomy[Title/Abstract])”.
The first search strategy yielded 179 articles, the
second search strategy yielded 149 articles and the third
search strategy yielded 103 articles. The authors
assessed the abstracts in all three searches. The “pre-
ferred reporting items for systematic reviews and meta-
analyses” (“PRISMA”) guideline [12] was followed.When it was not possible to ascertain article suitability
from its abstract alone we obtained the full text article
for further assessment.
As this was a systematic review, ethical board review
was not required. The primary outcome measure was
determining the survival benefit following the institution
of VA ECMO for refractory PCCS. The secondary out-
come measure was identifying the most commonly re-
ported APIs. The demographic data, APIs that had
reached statistical significance (P < 0.05) in each study
and crude data on outcome and follow-up, where avail-
able, were collated from each study. We then performed
meta-regression to assess whether the APIs identified
were significantly associated with survival.
Results
We identified 24 retrospective cohort studies that met
the inclusion criteria from 1992 to 2016 in the English
language literature. These studies as well as their
strengths and weaknesses, are summarized in Table 1. In
this review a cumulative total of 1926 patients required
VA ECMO for PCCS.
Survival and follow-up
In the largest cohort with the longest follow up available
in the literature, Rastan et al. reported results from 516
patients undergoing salvage ECMO for PCCS over a 12-
year period from 1996 to 2008. They reported a survival
to hospital discharge rate of 24.8% and a 13.7% 5-year
survival [5]. In another large study Doll et al. reported
results from 219 patients that underwent VA ECMO for
PCCS from 1997 to 2002. They reported a 39% survival
to hospital discharge and 17% 5-year survival [13].
In a multinational European study, Santarpino et al.
collated data from 11 European cardiac surgical centers
with cumulative results from 85 adult patients. Survival
rate to hospital discharge was reported as 40% with a
1-year survival rate of 29.3% [14].
Li et al. reported on 123 adult patients who were sal-
vaged with VA ECMO for refractory PCCS. They noted
that 56% of patients were successfully weaned from VA
ECMO and 34.1% survived to hospital discharge [15].
Elsharkawy et al. reported results from 233 patients with
survival to hospital discharge was reported at 36% [16].
In another cohort study Wu et al. reported outcomes from
110 patients of whom 61% were successfully weaned and
42% were successfully discharged home [17].
Bakhtiary et al. reported a 55% survival to ECMO
decannulation in their 45 patient cohort study, with a
total in-hospital mortality rate of 71% for the cohort. In
3 years, 77% of the survivors were still alive [18]. Ko
et al., analyzed the outcomes of 76 patients who under-
went ECMO for intractable PCCS. Although 60.5% of
patients survived to ECMO decannulation, 26.5%
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follow-up, all survivors were of NYHA I-II functional
status [19]. In a smaller cohort conducted by some of
the authors of this systematic review, 35% survival to
hospital discharge was observed and all survivors were
still alive at 12 months with NYHA class I-II [20].
Complications
Major haemorrhage was the most commonly reported
complication after institution of VA ECMO. It led to re-
intervention in almost half of the patients in a few good
quality studies [3, 5, 13, 14, 19, 20]. Factors such as the
insult of the original operation, heparin infusion and
heparin coated circuits are known to be the primary
causes of bleeding [13]. Renal failure requiring renal re-
placement therapy (RRT) was the next most commonly
reported complication [3, 5, 13, 20–22]. Stroke and sep-
sis also followed amongst the commonly encountered
complications (see Table 1). Distal limb ischaemia is one
of the most dreaded complications because if often leads
to major morbidity. The largest study in this systematic
review reported that almost 20% of patients with
peripheral VA ECMO developed a degree of distal limb
ischaemia. However, the use of a polyethylene tereph-
thalate tube graft (e.g. DacronR) as a sewn side arm to
the femoral or axillary arteries or the distal leg perfusion
cannula reduced distal limb ischaemia and fasciotomy
for compartment syndrome rate by almost 40% [5].
Adverse prognostic indicators
APIs that reached statistical significance and were
directly associated with mortality in each study are sum-
marized in Table 1. Advanced age (typically >70 years),
although perhaps not in isolation [5, 15, 17, 21, 23], was
the most commonly reported API. Development of renal
failure, whilst on VA ECMO that required RRT had a
strong association with mortality [5, 16, 23–25]. While
this common complication in the context of VA ECMO
for refractory PCCS is usually multifactorial. It is im-
perative to determine the most likely underlying aeti-
ology/ies for renal dysfunction as early as possible. The
following potential aetiologies should be identified and
corrected as early as possible postoperatively: renal hypo-
perfusion due to poor forward flows whilst on VA ECMO,
acute tubular necrosis due to prolonged hypotension pre-
ceding institution of support or syndrome of inappropriate
anti-diuretic hormone secretion (SIADH) [26]. It is worth
noting that the use of loop diuretics to address fluid over-
load or poor urine output leads to worsening renal dys-
function [26]. Rising serum lactate whilst on VA ECMO
[5, 15, 21] has also been reported as a strong predictor of
mortality. One study [5] advocated use of sodium bicar-
bonate infusion at an early stage to reduce metabolic acid-
osis and the organ damage that might ensue. Diabetesmellitus [5, 23], obesity [5, 23], gastrointestinal complica-
tions whilst on ECMO, high EuroSCORE (>20) and pro-
tracted ECMO support (>48 h) were also amongst the
commonly reported APIs [17, 21, 26, 27]. It must however
be acknowledged that prolonged ECMO support might
reflect the complexity of the original operation and the
patient’s poor clinical.
Although EuroSCORE was widely reported in the
studies, it was quoted in its three versions (i.e. the addi-
tive EuroSCORE, logistic EuroSCORE and EuroSCORE
II) over nearly 3 decades covered by this systematic re-
view. This variation made meta-analysis for EuroSCORE
as an API not possible.
Meta-analysis of survival to hospital discharge
We found that of the pooled total of 1926 patients, 594
(30.8%) survived to hospital discharge. We performed a
meta-analysis on the outcome of interest i.e. the propor-
tion of survivors. The software R was used with the
package “metaprop”**. Meta-analysis is conducted to es-
timate the true unknown success rate of a procedure, by
combining the results of several studies. Table 2 sum-
maries the variables included in the meta-analyses.
Figure 1 shows the forest plot describing each of the
study’s proportion of survivors with their 95% confi-
dence interval (CI).
Heterogeneity is present as defined by a statistically
significant I2 = 60%, which represents the percentage of
variability in the effect estimates due heterogeneity ra-
ther than random error. A value of I2 between 30 and
60% is considered as a moderate heterogeneity. By look-
ing at the forest plot, one can observe that study 11 is
well out from the rest. By removing study 11, the I2
value dropped to 59%. The overall proportion of survi-
vors is 31% (95% CI 0.29 to 0.34, p < 0.01, I2 = 60%), but
when considering random effect it raises to 33%.
Meta-regression of the adverse prognostic indicators
Meta-regression on the effects of moderators such as
age, usage of pre-VA ECMO IABP support and duration
of VA ECMO support was performed as these were the
most commonly and consistently reported variables by
most of the studies. Analysis showed that heterogeneity
had been observed due to random sampling and vari-
ation in the methods used for the studies (Table 3). In
order to account for at least part of the heterogeneity,
mixed effects models are used by including moderators.
This was also carried out using the package “metafor” in
R software. By including the moderators the heterogen-
eity statistic I2, which represents presence of variation in
an inter-study effect size (proportion of survivors)
dropped to 52.2% from the model without moderators
(previously 60% see forest plot, Fig. 1), which is classified
as moderate. We found that none of the coefficients of
Table 2 Summary of the information utilized to perform the meta-analysis
Study ID Author Country Year Average
age (yrs)
Preoperative
IABP usage
(no. pts)
Renal Failure
(no. pts)
Mean ECMO
support (days)
Diabetes mellitus
(no. pts)
Survivors Patient no.
1 Khorsandi UK 2015 71 15 2 5.5 0 5 15
2 Doll Germany 2004 61.3 144 122 NA 68 52 219
3 Khorsandi UK 2016 51 23 7 5.5 NA 8 23
4 Rastan Germany 2010 63.5 383 81 4.6 168 127 516
5 Slottosch Germany 2013 60 72 26 3.3 18 23 77
6 Hsu Taiwan 2010 63 51 16 7.5 19 26 51
7 Ko Taiwan 2002 56.8 44 28 NA NA 20 76
8 Muehrcke USA 1996 47.3 17 12 2.5 NA 7 22
9 Santarpino Europe 2015 64.6 16 7 4.5 25 8 20
10 Saeed Germany 2015 65 9 8 8.5 NA 2 9
11 Sajjad UK 2012 55.6 19 NA 4 NA 1 19
12 Mikus Italy 2013 53.1 14 7 5 4 6 14
13 Unosawa Japan 2013 64.4 39 15 2.6 9 14 47
14 Pokersnik USA 2012 65 29 16 4 19 15 49
15 Moreno Spain 2011 56.8 12 4 5.4 5 6 12
16 Wu Taiwan 2010 60 110 46 6 NA 46 110
17 Elsharkawy USA 2010 53.5 22 101 NA 50 84 233
18 Bakhtiary Germany 2008 60.1 30 39 6.4 38 13 45
19 Doll Germany 2003 59.8 95 64 2.8 NA 28 95
20 Wang Taiwan 1996 46.5 9 3 5.1 NA 6 18
21 Magovern USA 1994 61.6 21 4 1.8 4 11 21
22 Saxena USA 2015 76.8 45 30 4.2 17 11 45
23 Li China 2015 56.2 73 29 4.4 NA 42 123
24 Yan China 2010 50.5 18 30 3.1 NA 33 67
Abbreviations: NA not available, pts patients, IABP intra-aortic balloon pump, ECMO extra-corporeal membrane oxygenation, no. numbers, yrs. years
**R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
URL http://www.R-project.org/
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which means that there is no moderating effect of the
mean age, usage of pre-VA ECMO IABP and the mean
number of days on ECMO on the effect size. One of the
reasons of the lack of power for the test on the coeffi-
cients is the small sample sizes used in the studies.
Furthermore, we looked at the possibility of publica-
tion bias in the meta-analysis. Our analysis showed no
departure from symmetry in the funnel plot (Fig. 2),
hence absence of bias. This claim is supported by the
Egger’s test (p = 0.556).
Discussion
Our systematic review is the first of its kind to be pub-
lished, analyzing the efficacy of VA ECMO as a salvage
modality for refractory PCCS.
Refractory PCCS typically transpires at the end of a
complex and prolonged operation [28]. It can also occur
in an otherwise routine operation [5, 29] that hasencountered an unexpected technical difficulty e.g. an
iatrogenic injury to a vital structure during the course of
an operation. In either case the patient cannot be
weaned from cardiopulmonary bypass (CPB) with sur-
vivable haemodynamic and arterial blood gas parame-
ters, despite multiple inotropic support agents and IABP
[30]. Furthermore, adding to the predicament, such
cases typically encroach into “out-of-hours” [31] when
the operating theatre team is fatigued and there is a rela-
tive lack of availability of technical assistance and experi-
enced advice.
Why VA ECMO?
VA ECMO for refractory PCCS is typically established
centrally i.e. arterial line through the ascending aorta
and the venous line through the right atrium as part of the
continuum with CPB at the end of the operation [5, 29].
Although in principal the conduct of CPB and VA ECMO
are similar, there are several important advantages in
Fig. 1 Demonstrates the forest plot of the studies and the variables included in Table 2, describing each studies proportion of survivors (CI 95%)
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[32]. The CPB achieves full VA bypass at lower flow
rates (2–2.4 L/min/m2) with haematocrit levels of
around 20%, leading to lower than physiological
systemic oxygen delivery (DO2) [32]. A large dose
(300–400 Units/kg) of unfractionated heparin (UH) is
required to run CPB, as it is an “open circuit” with a
venous reservoir (stagnant blood). In addition, full VA
bypass is said to cause stasis of blood in the cardiac
chambers and the pulmonary circulation warranting
higher activated clotting times (ACT). VA ECMO on
the other hand is more physiological. It uses partial VA
bypass through a “closed circuit” (without a venous res-
ervoir) and shorter tubing, typically in normothermia,
with normal haematocrit levels, aiming for near normal
DO2. As VA ECMO allows venous return to the heart,
it allows cardiac ejection and less risk of thrombosis,
thereby requiring minimal doses of UH as compared to
CPB. This in-turn leads to fewer rates of postoperative
bleeding complications requiring re-exploration whilst
on MCS. VA ECMO is more versatile and is more easily
manageable in the intensive care unit (ICU) setting for
often-prolonged periods of time (i.e. days-weeks),Table 3 Shows the coefficients of the meta-regression for each of t
Covariate Coefficient Standard
(logit scale) Error
Intercept 0.669 0.824
Mean Age (yr) −0.028 0.015
IABP rate 0.206 0.446
Mean ECMO (days) 0.049 0.060unlike CPB, which is geared more towards short-term
support (i.e. a few hours) [32]. The VA ECMO line tub-
ing can be tunneled through the skin to allow chest
closure. This maybe significant in that “incomplete ster-
nal closure” has been reported as an independent pre-
dictor of mortality, as identified in a study by Unosawa
et al. [27]. However, line change over to other sites,
with axillary arterial, femoral arterial and femoral venous
cannulation sites have previously been reported [5, 13].
Occasionally combined right atrial and femoral venous
cannulation have been used to improve venous drainage
[5]. Vascular access can be established with either surgical
cut down or by Seldinger techniques. Some sew a side
arm tube graft to the artery or use a distal perfusion can-
nula to reduce the risk of distal limb ischaemia and com-
partment syndrome (see complications) [5, 13].
Although ECMO is a valuable salvage modality, it is
expensive [33]. It is very resource intensive due to its
high demand on the ICU staff. It requires skilled staff
performing high frequency monitoring for its safe appli-
cation and maintenance [33]. These factors can pose a
significant burden particularly on small and intermediate
sized cardiac surgical centers, where the work force andhe moderators in a logit scale
95% 95% Z-value 2-sided
Lower Upper P-value
−0.946 2.284 0.810 0.417
−0.057 0.001 −1.900 0.058
−0.667 1.080 0.460 0.643
−0.068 0.166 0.820 0.412
Fig. 2 Demonstrates the funnel plot on the analysis on publication bias, which shows no departure from symmetry, hence absence of bias
(Egger’s test p = 0.556)
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average, require more prolonged ICU stay than elective
cases thereby leading to increased cancellation of elective
and sometimes urgent cardiac surgical operations. As
such, indiscriminant use of VA ECMO can result in major
disturbance to an already stretched service [30].
Some centers in the UK rely on transplant centers for
advice regarding whether or not to place PCCS patients
on VA ECMO. If these patients are commenced on
ECMO, they are transferred over to the larger transplant
centers for further management [30, 34]. Critics had ar-
gued that, if only transplant units are funded to provide
ECMO for PCCS support, similar patients at non-
transplant cardiac surgical centers are denied of a life
saving therapy [35]. In reality the use of VA ECMO for
PCCS is not formally commissioned by the National
Health Service (NHS) in the UK and the cost of treat-
ment has to be absorbed by individual hospitals.
Kashani et al. [36], published an abstract on a system-
atic review covering only 11 case series with a cumula-
tive pool of 1328 patients whereas our review covers 24
studies with a cumulative pool of 1926 patients. The sur-
vival rate to hospital discharge reported by Kashani et al.
of 31.48% was comparable to our report of 30.8%. In
their systematic review, they found similar APIs to our
systematic review such as advanced age, elevated serum
lactate after initiation of ECMO and renal failure [36].Our meta-regression of APIs such as mean age, pre-VA
ECMO use of IABP, effect of renal failure and mean
ECMO duration however showed no statistically signifi-
cant correlation between these parameters and survival,
mainly due to the small sample sizes and presence of
wide heterogeneity amongst study populations (Table 3).
This topic remains a controversial one with ethical
and financial considerations for any cardiac surgical ser-
vice. The decision as to whether or not to institute VA
ECMO in the setting of PCCS remains difficult. Institu-
tion of VA ECMO for PCCS is usually not planned and
the aetiology of the patient’s lack of progress may not be
immediately apparent [19]. A study of 100 trans-catheter
aortic valve implantation (TAVI) patients, reported that
anticipation for ECMO and institution of this mode of
support prophylactically in the “high-risk” category on
the EuroSCORE scale would potentially prevent the
need for salvage VA ECMO, in a less optimal and con-
trolled clinical setting, and carry better outcomes. In
this study all-cause mortality occurred in none of the
high-risk patients undergoing prophylactic VA ECMO
(although p > 0.05) [37].
The literature demonstrates overwhelming evidence
pointing towards reasonable survival rate to hospital dis-
charge for patients undergoing ECMO for an otherwise
universally fatal clinical condition. Furthermore reason-
able intermediate-term and long-term survival rates as
Khorsandi et al. Journal of Cardiothoracic Surgery  (2017) 12:55 Page 11 of 13well as good quality of life have been reported in a few
studies (Table 1) mainly for the survivors that do not
manifest the APIs (see results). Major life threatening
ECMO complications are common. We advocate a
multidisciplinary team (MDT) approach to decision
making for institution of ECMO in the context of refrac-
tory PCCS [29]. We recommend that given the ethical
and cost implications, the surgeon, the anaesthetist, the
on-call intensivist, the on-call perfusionist and a cardiac
surgeon not involved in the operation (e.g. the on-call
cardiac surgeon) should be involved in the decision mak-
ing in whether or not to institute ECMO for refractory
PCCS on a case-by-case basis [20]. We believe that due
to the complexity of such cases protocols may not be
an adequate substitute for an MDT approach to
decision-making and management of such complex pa-
tients [5, 20]. Finally, in order to both preserve the pa-
tients’ autonomy and aid decision-making in the event
of encountering refractory PCCS, we advocate that the
possibility of the need for VA ECMO along with its
pros and cons should be discussed with high-risk pa-
tients preoperatively and informed consent should be
obtained in this regard.
Conclusions
We believe that VA ECMO provides a survival benefit
for a significant proportion of patients with refractory
PCCS, which is invariably a fatal clinical state. For hos-
pital survivors, a reasonable intermediate and long-term
functional outcome can be expected albeit at the ex-
pense of prolonged and often ridden hospital stay. We
identified advanced age, renal failure and prolonged
VA ECMO support to be commonly reported APIs.
This claim however could not be supported by meta-
regression due to small patient numbers and hetero-
geneity of the patient populations. Risk stratification
tools such as the EuroSCORE can be utilized to antici-
pate the need for prophylactic perioperative VA ECMO
in the high-risk category. The reported APIs should be
taken into consideration before institution of and on-
going treatment with this laborious, invasive and ex-
pensive therapeutic modality.
Limitations
Most of the evidence available in the literature, including
our analysis, pertains to older studies from the 1990s. Due
to the nature of PCCS, randomization would not be ap-
propriate and the studies typically constitute heteroge-
neous patient populations leading to skewing of the data.
As for the pre-VA ECMO IABP application subgroup ana-
lysis, a few studies had not reported this data. In such
studies we assumed that, in principal, all patients would
have had IABP pre-VA ECMO institution. Hence the out-
come of data analysis errs on the side of IABP usage.Small number of studies and heterogeneity of the patient
populations meant that the statistical tests were not strong
enough to detect statistical significance in our study. The
data on EuroSCORE, rising lactate whilst on ECMO and
the rate of obesity was not reported by enough studies to
constitute a more objective analysis, hence deriving any
solid conclusions regarding these indicators was difficult.
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